Related Experiment Videos
Complete resistance after maximal dose of rocuronium
Annalisa Capuano1, Maria Giuseppa Sullo1, Concetta Rafaniello1
1Department of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Caserta, Italy.
Journal of Pharmacology & Pharmacotherapeutics
|August 28, 2015
Summary
This case report details a 20-year-old male exhibiting complete resistance to rocuronium, a neuromuscular blocking agent. This resistance may be linked to concurrent glucocorticoid therapy, highlighting potential drug interactions.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Rocuronium is a non-depolarizing neuromuscular blocking agent (NDNMBA) used in anesthesia for tracheal intubation and muscle relaxation.
- Resistance to NMBAs is anecdotally reported and can be influenced by pathologic states and concurrent drug therapies.
Observation:
- A 20-year-old male patient demonstrated complete resistance to rocuronium.
- This unusual resistance occurred despite standard anesthetic procedures.
Findings:
- Concurrent glucocorticoid therapy was noted in the patient.
- Glucocorticoids may potentially antagonize the effects of rocuronium, leading to resistance.
Implications:
- This case underscores the importance of considering concomitant medications when NMBA efficacy is unexpectedly reduced.
- Further research into glucocorticoid-induced resistance to NMBAs is warranted to optimize anesthetic management.